Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 55

1.

Comparative analysis of various in vitro COT kinase assay formats and their applications in inhibitor identification and characterization.

Jia Y, Quinn CM, Clabbers A, Talanian R, Xu Y, Wishart N, Allen H.

Anal Biochem. 2006 Mar 15;350(2):268-76. Epub 2005 Nov 30.

PMID:
16356459
2.

Identification of 4-anilino-3-quinolinecarbonitrile inhibitors of mitogen-activated protein/extracellular signal-regulated kinase 1 kinase.

Mallon R, Feldberg L, Kim S, Collins K, Wojciechowicz D, Kohler C, Kovacs D, Discafani C, Zhang N, Wu B, Floyd B, Powell D, Berger D.

Mol Cancer Ther. 2004 Jun;3(6):755-62.

3.

Identification of a novel human kinase supporter of Ras (hKSR-2) that functions as a negative regulator of Cot (Tpl2) signaling.

Channavajhala PL, Wu L, Cuozzo JW, Hall JP, Liu W, Lin LL, Zhang Y.

J Biol Chem. 2003 Nov 21;278(47):47089-97. Epub 2003 Sep 15.

4.

Purification and kinetic characterization of recombinant human mitogen-activated protein kinase kinase kinase COT and the complexes with its cellular partner NF-kappa B1 p105.

Jia Y, Quinn CM, Bump NJ, Clark KM, Clabbers A, Hardman J, Gagnon A, Kamens J, Tomlinson MJ, Wishart N, Allen H.

Arch Biochem Biophys. 2005 Sep 1;441(1):64-74.

PMID:
16087150
5.

Identification of a selective thieno[2,3-c]pyridine inhibitor of COT kinase and TNF-alpha production.

Cusack K, Allen H, Bischoff A, Clabbers A, Dixon R, Fix-Stenzel S, Friedman M, Gaumont Y, George D, Gordon T, Grongsaard P, Janssen B, Jia Y, Moskey M, Quinn C, Salmeron A, Thomas C, Wallace G, Wishart N, Yu Z.

Bioorg Med Chem Lett. 2009 Mar 15;19(6):1722-5. doi: 10.1016/j.bmcl.2009.01.088. Epub 2009 Jan 30.

PMID:
19217782
6.

Luteolin, a novel natural inhibitor of tumor progression locus 2 serine/threonine kinase, inhibits tumor necrosis factor-alpha-induced cyclooxygenase-2 expression in JB6 mouse epidermis cells.

Kim JE, Son JE, Jang YJ, Lee DE, Kang NJ, Jung SK, Heo YS, Lee KW, Lee HJ.

J Pharmacol Exp Ther. 2011 Sep;338(3):1013-22. doi: 10.1124/jpet.111.179200. Epub 2011 Jun 24.

7.

Cot/Tpl-2 protein kinase as a target for the treatment of inflammatory disease.

George D, Salmeron A.

Curr Top Med Chem. 2009;9(7):611-22. Review.

PMID:
19689369
8.

Phosphorylation of threonine 290 in the activation loop of Tpl2/Cot is necessary but not sufficient for kinase activity.

Luciano BS, Hsu S, Channavajhala PL, Lin LL, Cuozzo JW.

J Biol Chem. 2004 Dec 10;279(50):52117-23. Epub 2004 Oct 4.

9.

Selective in vivo inhibition of mitogen-activated protein kinase activation using cell-permeable peptides.

Kelemen BR, Hsiao K, Goueli SA.

J Biol Chem. 2002 Mar 8;277(10):8741-8. Epub 2001 Dec 26.

10.

Development of a 1-microl scale assay for mitogen-activated kinase kinase 7 using 2-D fluorescence intensity distribution analysis anisotropy.

Wright PA, Boyd HF, Bethell RC, Busch M, Gribbon P, Kraemer J, Lopez-Calle E, Mander TH, Winkler D, Benson N.

J Biomol Screen. 2002 Oct;7(5):419-28.

PMID:
14599357
11.

Cancer Osaka thyroid (Cot) phosphorylates Polo-like kinase (PLK1) at Ser137 but not at Thr210.

Wu B, Jiang P, Mu Y, Wilmouth RC.

Biol Chem. 2009 Dec;390(12):1271-7. doi: 10.1515/BC.2009.141.

PMID:
19804365
12.

Involvement of Cot/Tp12 in bone loss during periodontitis.

Ohnishi T, Okamoto A, Kakimoto K, Bandow K, Chiba N, Matsuguchi T.

J Dent Res. 2010 Feb;89(2):192-7. doi: 10.1177/0022034509353405.

PMID:
20089988
13.

Current status of HTRF(®) technology in kinase assays.

Jia Y.

Expert Opin Drug Discov. 2008 Dec;3(12):1461-74. doi: 10.1517/17460440802518171.

PMID:
23506109
14.

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis.

Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, Cao Y, Shujath J, Gawlak S, Eveleigh D, Rowley B, Liu L, Adnane L, Lynch M, Auclair D, Taylor I, Gedrich R, Voznesensky A, Riedl B, Post LE, Bollag G, Trail PA.

Cancer Res. 2004 Oct 1;64(19):7099-109.

15.

Discovery and characterization of non-ATP site inhibitors of the mitogen activated protein (MAP) kinases.

Comess KM, Sun C, Abad-Zapatero C, Goedken ER, Gum RJ, Borhani DW, Argiriadi M, Groebe DR, Jia Y, Clampit JE, Haasch DL, Smith HT, Wang S, Song D, Coen ML, Cloutier TE, Tang H, Cheng X, Quinn C, Liu B, Xin Z, Liu G, Fry EH, Stoll V, Ng TI, Banach D, Marcotte D, Burns DJ, Calderwood DJ, Hajduk PJ.

ACS Chem Biol. 2011 Mar 18;6(3):234-44. doi: 10.1021/cb1002619. Epub 2011 Jan 20.

PMID:
21090814
16.

Kinetic characterization of novel pyrazole TGF-beta receptor I kinase inhibitors and their blockade of the epithelial-mesenchymal transition.

Peng SB, Yan L, Xia X, Watkins SA, Brooks HB, Beight D, Herron DK, Jones ML, Lampe JW, McMillen WT, Mort N, Sawyer JS, Yingling JM.

Biochemistry. 2005 Feb 22;44(7):2293-304.

PMID:
15709742
17.
18.
19.

Designing in vitro assays for drug discovery: a study with the human MAP3 kinase COT.

Jia Y, Quinn CM, Talanian RV.

Expert Opin Drug Discov. 2007 Jul;2(7):909-15. doi: 10.1517/17460441.2.7.909.

PMID:
23484811
20.

Supplemental Content

Support Center